Immunomedics Offers Progress of Antibody-Drug Conjugate Programs at NY Biotech Association Conference

Immunomedics, Inc. IMMU, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, announced that during the Company's presentation at the New York Biotechnology Association's Annual Meeting yesterday, President and CEO, Cynthia L. Sullivan, updated the audience on the progress of the antibody-drug conjugate (ADC) programs. Both ADC product candidates involve SN-38, the active metabolite of irinotecan (used to treat metastatic colorectal and other solid cancers), conjugated by the Company's proprietary technology to labetuzumab (anti-CEACAM5 humanized monoclonal antibody; IMMU-130) or the anti-TROP-2 humanized antibody, hRS7 (IMMU-132). Whereas IMMU-130 is being studied in advanced colorectal cancer patients who have failed irinotecan therapy, IMMU-132 is being tested in 13 cancer types, including colorectal, triple-negative breast, bladder, pancreas, prostate, kidney, and ovarian cancers.